Juan Gimeno Blanes

List of Publications by Year
in descending order

132	15,603	57719	17090
papers	citations	44 h-index	122 g-index

154	154	154	13288
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal, 2014, 35, 2733-2779.	1.0	3,469
2	Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2013, 34, 2636-2648.	1.0	2,436
3	A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM) Tj ETQq1 1 0.784314 rgBT /Ove	1.0	848
4	Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. European Heart Journal, 2016, 37, 1850-1858.	1.0	757
5	Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 2003, 42, 873-879.	1.2	484
6	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2020, 396, 759-769.	6.3	481
7	Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet, The, 2001, 357, 420-424.	6.3	436
8	Natural history and familial characteristics of isolated left ventricular non-compaction. European Heart Journal, 2005, 26, 187-192.	1.0	427
9	Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. European Heart Journal, 2006, 27, 1933-1941.	1.0	352
10	Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2013, 34, 1448-1458.	1.0	346
11	Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. Journal of the American College of Cardiology, 2016, 68, 2440-2451.	1.2	340
12	Mutations in the NOTCH pathway regulator MIB1 cause left ventricular noncompaction cardiomyopathy. Nature Medicine, 2013, 19, 193-201.	15.2	296
13	Prospective evaluation of relatives for familial arrhythmogenic right ventricular cardiomyopathy/dysplasia reveals a need to broaden diagnostic criteria. Journal of the American College of Cardiology, 2002, 40, 1445-1450.	1.2	285
14	Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. Journal of Clinical Investigation, 2003, 111, 209-216.	3.9	278
15	Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation. Journal of the American College of Cardiology, 2008, 51, 818-825.	1.2	256
16	Prevalence of Fabry Disease in a Cohort of 508 Unrelated Patients With Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2007, 50, 2399-2403.	1.2	254
17	Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart, 2005, 92, 785-791.	1.2	235
18	Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. Journal of Clinical Investigation, 2003, 111, 209-216.	3.9	169

#	Article	IF	Citations
19	Prevalence, Clinical Significance, and Genetic Basis of Hypertrophic Cardiomyopathy With Restrictive Phenotype. Journal of the American College of Cardiology, 2007, 49, 2419-2426.	1.2	167
20	Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. European Heart Journal, 2009, 30, 2599-2605.	1.0	160
21	Triage strategy for urgent management of cardiac tamponade: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2014, 35, 2279-2284.	1.0	154
22	Genetics of hypertrophic cardiomyopathy: A review of current state. Clinical Genetics, 2018, 93, 3-14.	1.0	130
23	Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy. Heart, 2005, 91, 920-925.	1.2	126
24	Prediction of thromboâ€embolic risk in patients with hypertrophic cardiomyopathy (<scp>HCM</scp>) Tj ETQq0 0 0 rgBT /Overlock 10	2.9	114
25	Genetics of myocarditis in arrhythmogenic right ventricular dysplasia. Heart Rhythm, 2015, 12, 766-773.	0.3	111
26	An expert consensus document on the management of cardiovascular manifestations of Fabry disease. European Journal of Heart Failure, 2020, 22, 1076-1096.	2.9	96
27	The Cardiomyopathy Registry of the EUREObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. European Heart Journal, 2018, 39, 1784-1793.	1.0	94
28	Desmoplakin truncations and arrhythmogenic left ventricular cardiomyopathy: characterizing a phenotype. Europace, 2014, 16, 1838-1846.	0.7	87
29	Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. European Heart Journal, 2013, 34, 2529-2537.	1.0	84
30	Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. American Heart Journal, 2008, 156, 85-91.	1.2	80
31	The current role of next-generation DNA sequencing in routine care of patients with hereditary cardiovascular conditions: a viewpoint paper of the European Society of Cardiology working group on myocardial and pericardial diseases and members of the European Society of Human Genetics. European Heart Journal, 2015, 36, 1367-1370.	1.0	75
32	Clinical Phenotypes and Prognosis of Dilated Cardiomyopathy Caused by Truncating Variants in the TTN Gene. Circulation: Heart Failure, 2020, 13, e006832.	1.6	75
33	Progressive left ventricular remodeling in patients with hypertrophic cardiomyopathy and severe left ventricular hypertrophy. Journal of the American College of Cardiology, 2004, 44, 398-405.	1.2	72
34	Predictors of atrial fibrillation in hypertrophic cardiomyopathy. Heart, 2017, 103, 672-678.	1.2	71
35	Mortality Among Referral Patients With Hypertrophic Cardiomyopathy vs the General European Population. JAMA Cardiology, 2020, 5, 73.	3.0	69
36	A newKCNQ1mutation at the S5 segment that impairs its association with KCNE1 is responsible for short QT syndrome. Cardiovascular Research, 2015, 107, 613-623.	1.8	67

#	Article	IF	Citations
37	Mid-range left ventricular ejection fraction: Clinical profile and cause of death in ambulatory patients with chronic heart failure. International Journal of Cardiology, 2017, 240, 265-270.	0.8	66
38	Genetic basis of familial dilated cardiomyopathy patients undergoing heart transplantation. Journal of Heart and Lung Transplantation, 2016, 35, 625-635.	0.3	60
39	Formin Homology 2 Domain Containing 3 (FHOD3) Is a Genetic Basis for Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2018, 72, 2457-2467.	1.2	59
40	Insights into genotype-phenotype correlation in hypertrophic cardiomyopathy. Findings from 18 Spanish families with a single mutation in MYBPC3. Heart, 2010, 96, 1980-1984.	1.2	58
41	Filamin C variants are associated with a distinctive clinical and immunohistochemical arrhythmogenic cardiomyopathy phenotype. International Journal of Cardiology, 2020, 307, 101-108.	0.8	56
42	Phenotype and prognostic correlations of the converter region mutations affecting the Î² myosin heavy chain. Heart, 2015, 101, 1047-1053.	1.2	54
43	Diagnostic Approach to Unexplained Cardiac Arrest (from the FIVI-Gen Study). American Journal of Cardiology, 2015, 116, 894-899.	0.7	46
44	Usefulness of N-Terminal Pro-B-Type Natriuretic Peptide Levels to Predict Exercise Capacity in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2006, 98, 515-519.	0.7	42
45	Insights Into the Role of microRNAs in Cardiac Diseases: From Biological Signalling to Therapeutic Targets. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2009, 7, 82-90.	0.4	42
46	Efficacy of percutaneous closure of patent foramen ovale: comparison among three commonly used occluders. Heart, 2011, 97, 394-399.	1.2	42
47	Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation. International Journal of Cardiology, 2017, 248, 232-238.	0.8	41
48	Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator. European Heart Journal, 2022, 43, 3053-3067.	1.0	41
49	Sex-related differences in cardiomyopathies. International Journal of Cardiology, 2019, 286, 239-243.	0.8	39
50	Penetrance and Risk Profile in Inherited Cardiac Diseases Studied in a Dedicated Screening Clinic. American Journal of Cardiology, 2009, 104, 406-410.	0.7	38
51	Percutaneous coronary intervention with rotational atherectomy for severely calcified unprotected left main: Immediate and twoâ€years followâ€up results. Catheterization and Cardiovascular Interventions, 2012, 80, 215-220.	0.7	36
52	Left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy. European Heart Journal, 2006, 27, 3073-3073.	1.0	34
53	Variables Associated With Contrast-Enhanced Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy: Clinical Implications. Journal of Cardiac Failure, 2008, 14, 414-419.	0.7	33
54	Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysis. Heart, 2019, 105, heartjnl-2018-313700.	1.2	31

#	Article	IF	Citations
55	A mutation in the Zâ€line Cypher/ZASP protein is associated with arrhythmogenic right ventricular cardiomyopathy. Clinical Genetics, 2015, 88, 172-176.	1.0	28
56	Intervencionismo coronario en lesiones severamente calcificadas mediante aterectomÃa rotacional y stent liberador de paclitaxel: resultados tras un aÃ±o de seguimiento. Revista Espanola De Cardiologia, 2010, 63, 107-110.	0.6	27
57	Computer versus cardiologist: Is a machine learning algorithm able to outperform an expert in diagnosing a phospholamban p.Arg14del mutation on the electrocardiogram?. Heart Rhythm, 2021, 18, 79-87.	0.3	26
58	RNA sequencing-based transcriptome profiling of cardiac tissue implicates novel putative disease mechanisms in FLNC-associated arrhythmogenic cardiomyopathy. International Journal of Cardiology, 2020, 302, 124-130.	0.8	23
59	Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry. ESC Heart Failure, 2021, 8, 95-105.	1.4	23
60	Mutation in <scp>JPH2</scp> cause dilated cardiomyopathy. Clinical Genetics, 2016, 90, 468-469.	1.0	20
61	The EP300/TP53 pathway, a suppressor of the Hippo and canonical WNT pathways, is activated in human hearts with arrhythmogenic cardiomyopathy in the absence of overt heart failure. Cardiovascular Research, 2022, 118, 1466-1478.	1.8	20
62	Unclassifiable arrhythmic cardiomyopathy associated with Emeryâ€“Dreifuss caused by a mutation in <scp>FHL1</scp>. Clinical Genetics, 2016, 90, 171-176.	1.0	19
63	Inverted U-Shaped Relation Between the Risk of Sudden Cardiac Death and Maximal Left Ventricular Wall Thickness in Hypertrophic Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	2.1	19
64	ESC EORP Cardiomyopathy Registry: realâ€life practice of genetic counselling and testing in adult cardiomyopathy patients. ESC Heart Failure, 2020, 7, 3013-3021.	1.4	19
65	A study of the <scp>SCN5A</scp> gene in a cohort of 76 patients with Brugada syndrome. Clinical Genetics, 2013, 83, 530-538.	1.0	17
66	COMPUTER ASSISTED RETINAL VESSEL TORTUOSITY EVALUATION IN NOVEL MUTATION FABRY DISEASE. Retina, 2017, 37, 592-603.	1.0	17
67	Soluble and Particulate Organophosphorus Neuropathy Target Esterase in Brain and Sciatic Nerve of the Hen, Cat, Rat, and Chick. Journal of Neurochemistry, 1993, 61, 2164-2168.	2.1	16
68	In-Hospital and Long-Term Mortality in Women With Acute Myocardial Infarction Treated by Primary Angioplasty. Revista Espanola De Cardiologia (English Ed), 2006, 59, 1113-1122.	0.4	16
69	Somatic <i>MYH7</i>, <i>MYBPC3</i>, <i>TPM1</i>, <i>TNNT2</i> and <i>TNNI3</i> Mutations in Sporadic Hypertrophic Cardiomyopathy. Circulation Journal, 2013, 77, 2358-2365.	0.7	15
70	Heterophile antibodies produce spuriously elevated concentrations of cardiac Troponin I in patients with Legionella pneumophila. Clinical Biochemistry, 2005, 38, 584-587.	0.8	14
71	Plan of Action for Inherited Cardiovascular Diseases: Synthesis of Recommendations and Action Algorithms. Revista Espanola De Cardiologia (English Ed), 2016, 69, 300-309.	0.4	14
72	Backscatter evaluation of myocardial functional and textural findings in children with right ventricular pressure and/or volume overload. American Journal of Cardiology, 2004, 93, 594-597.	0.7	12

#	Article	IF	Citations
73	Eco-Doppler de ejercicio en pacientes con miocardiopatÃa hipertrÃ³fica. Factores determinantes de la limitaciÃ³n funcional. Revista Espanola De Cardiologia, 2013, 66, 98-103.	0.6	12
74	ALG12â€CDG: An unusual patient without intellectual disability and facial dysmorphism, and with a novel variant. Molecular Genetics & Genomic Medicine, 2020, 8, e1304.	0.6	12
75	Implantable Cardioverter Defibrillator and Hypertrophic Cardiomyopathy. Experience at Three Centers. Revista Espanola De Cardiologia (English Ed), 2006, 59, 537-544.	0.4	11
76	Heat stroke, an unusual trigger of Brugada electrocardiogram. American Journal of Emergency Medicine, 2009, 27, 634.e1-634.e3.	0.7	11
77	CaracterÃsticas de la muerte sÃºbita en las cardiopatÃas hereditarias. Revista Espanola De Cardiologia, 2010, 63, 268-276.	0.6	11
78	AblaciÃ³n septal alcohÃ³lica en la miocardiopatÃa hipertrÃ³fica, una oportunidad para aprovechar. Revista Espanola De Cardiologia, 2012, 65, 314-318.	0.6	11
79	D242N, a KV7.1 LQTS mutation uncovers a key residue for IKs voltage dependence. Journal of Molecular and Cellular Cardiology, 2017, 110, 61-69.	0.9	11
80	Atrial fibrillation, anticoagulation management and risk of stroke in the Cardiomyopathy/Myocarditis registry of the EURObservational Research Programme of the European Society of Cardiology. ESC Heart Failure, 2020, 7, 3601-3609.	1.4	11
81	A Novel Founder Mutation in MYBPC3: Phenotypic Comparison With the Most Prevalent MYBPC3 Mutation in Spain. Revista Espanola De Cardiologia (English Ed), 2017, 70, 105-114.	0.4	10
82	Genetics of feline hypertrophic cardiomyopathy. Clinical Genetics, 2020, 98, 203-214.	1.0	10
83	Prognostic value of the Thrombolysis in Myocardial Infarction risk score in a unselected population with chest pain. Construction of a new predictive model. American Journal of Emergency Medicine, 2008, 26, 439-445.	0.7	8
84	Unusual presentation of acute coronary syndrome. Bilateral coronary dissection after car accident. American Journal of Emergency Medicine, 2009, 27, 1024.e3-1024.e5.	0.7	7
85	MutaciÃ³n p.Arg14del en fosfolambÃ¡n en una familia espaÃ±ola con miocardiopatÃa arritmogÃ©nica: evidencia de una mutaciÃ³n europea fundadora. Revista Espanola De Cardiologia, 2015, 68, 346-349.	0.6	7
86	Alcohol Septal Ablation in Hypertrophic Cardiomyopathy: An Opportunity to Be Taken. Revista Espanola De Cardiologia (English Ed), 2012, 65, 314-318.	0.4	6
87	Phospholamban p.arg14del Mutation in a Spanish Family With Arrhythmogenic Cardiomyopathy: Evidence for a European Founder Mutation. Revista Espanola De Cardiologia (English Ed), 2015, 68, 346-349.	0.4	6
88	Fenotipo heterogÃ©neo del sÃndrome de QT largo causado por la mutaciÃ³n KCNH2-H562R: importancia del estudio genÃ©tico familiar. Revista Espanola De Cardiologia, 2015, 68, 861-868.	0.6	6
89	Impact of SARSâ€Covâ€2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry. ESC Heart Failure, 2022, 9, 2189-2198.	1.4	6
90	Comprehensive clinical evaluation of a large Spanish family with Anderson-Fabry disease, novel GLA mutation and severe cardiac phenotype. Medicina ClÃnica, 2014, 142, 497-504.	0.3	5

#	Article	IF	Citations
91	MiocardiopatÃa hipertrÃ³fica. Medicina ClÃnica, 2018, 150, 434-442.	0.3	5
92	Trabeculated Myocardium in Hypertrophic Cardiomyopathy: Clinical Consequences. Journal of Clinical Medicine, 2020, 9, 3171.	1.0	5
93	Embolia coronaria tras implante percutÃ¡neo de prÃ³tesis valvular aÃ³rtica. Revista Espanola De Cardiologia, 2009, 62, 1074-1075.	0.6	4
94	Exercise Eco-Doppler in Hypertrophic Cardiomyopathy Patients. Determinant Factors of Exercise Intolerance. Revista Espanola De Cardiologia (English Ed), 2013, 66, 98-103.	0.4	4
95	Arrhythmogenic right ventricular cardiomyopathy. Lancet, The, 2015, 385, 662.	6.3	4
96	Unexpected autopsy findings after sudden cardiac death: Cardiovascular myxoedema and endocardial fibroelastosis. International Journal of Cardiology, 2015, 182, 281-283.	0.8	4
97	Value of the â€œStanding Testâ€•in the Diagnosis and Evaluation of Beta-blocker Therapy Response in Long QT Syndrome. Revista Espanola De Cardiologia (English Ed), 2017, 70, 907-914.	0.4	4
98	Genetic Factors Involved in Cardiomyopathies and in Cancer. Journal of Clinical Medicine, 2020, 9, 1702.	1.0	4
99	Towards an Enhanced Tool for Quantifying the Degree of LV Hyper-Trabeculation. Journal of Clinical Medicine, 2021, 10, 503.	1.0	4
100	An R1632C variant in the SCN5A gene causing Brugada syndrome. Molecular Medicine Reports, 2016, 13, 4677-4680.	1.1	3
101	Hypertrophic or hypertensive cardiomyopathy?. International Journal of Cardiology, 2016, 203, 891-892.	0.8	3
102	Prospective follow-up in various subtypes of cardiomyopathies: insights from the ESC EORP Cardiomyopathy Registry. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 134-142.	1.8	3
103	Detection and estimation of T wave alternans with matched filter and nonparametric bootstrap test. , 2008, , .		2
104	Characteristics of Sudden Death in Inherited Heart Disease. Revista Espanola De Cardiologia (English) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.4	2
105	Modelo de intervenciÃ³n coronaria percutÃ¡nea primaria en la RegiÃ³n de Murcia. Revista Espanola De Cardiologia Suplementos, 2011, 11, 28-34.	0.2	2
106	Heterogeneous Phenotype of Long QT Syndrome Caused by the KCNH2-H562R Mutation: Importance of Familial Genetic Testing. Revista Espanola De Cardiologia (English Ed), 2015, 68, 861-868.	0.4	2
107	Penetrancia familiar en la parada cardÃaca en ausencia de cardiopatÃa aparente: observaciones del estudio FIVI-Gen. Cardiocore, 2016, 51, 30-36.	0.0	2
108	Valor del Â«test de bipedestaciÃ³nÂ» en el diagnÃ³stico y la evaluaciÃ³n de la respuesta al tratamiento con bloqueadores beta en el sÃndrome de QT largo. Revista Espanola De Cardiologia, 2017, 70, 907-914.	0.6	2

#	Article	IF	Citations
109	Phenotypic Characterization of a Family With An In-frame Deletion in the DMD Gene and Variable Penetrance. Current Gene Therapy, 2018, 18, 246-251.	0.9	2
110	A study of the pathogenicity of variants in familial heart disease. The value of cosegregation. American Journal of Translational Research (discontinued), 2019, 11, 1724-1735.	0.0	2
111	Evidence for reciprocal network interactions between injured hearts and cancer. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
112	Gadolinium-Enhanced Cardiovascular Magnetic Resonance and Exercise Capacity in Hypertrophic Cardiomyopathy. Revista Espanola De Cardiologia (English Ed), 2008, 61, 853-860.	0.4	1
113	CRT-177 Ulnar Artery, is it as Safe as the Radial for Cardiac Catheterization?. JACC: Cardiovascular Interventions, 2014, 7, S32.	1.1	1
114	Factor de transcripciÃ³n TBX1 en el remodelado cardiaco asociado al infarto de miocardio. Revista Espanola De Cardiologia, 2016, 69, 1042-1050.	0.6	1
115	La importancia del estudio familiar y genÃ©tico: la mutaciÃ³n p.L3778F en el receptor de la rianodina probablemente no cause un fenotipo tan grave. Revista Espanola De Cardiologia, 2016, 69, 702-704.	0.6	1
116	MiocardiopatÃa hipertrÃ³fica en 2018: Â¿en quÃ© punto estamos?. Cardiocore, 2018, 53, 148-151.	0.0	1
117	Short QT and dilated cardiomyopathy. A phenotype with a good prognosis?. International Journal of Cardiology, 2011, 151, 356-357.	0.8	0
118	Hypertrophic cardiomyopathy or storage cardiomyopathy? Role of genetics to predict outcome. International Journal of Cardiology, 2011, 151, 380-381.	0.8	0
119	Atypical Cause of Syncope in Patients with Brugada Syndrome. The European Journal of Cardiovascular Medicine, 2013, 11, .	1.0	0
120	Author's reply. Europace, 2015, 17, 334-337.	0.7	0
121	New haplotype of Fabry disease among patients screened for left ventricular hypertrophy of unknown cause. Molecular Genetics and Metabolism, 2015, 114, S29-S30.	0.5	0
122	Individualized therapy in patients with Fabry disease: is it a feasible strategy for rare diseases?. Expert Opinion on Orphan Drugs, 2016, 4, 1199-1206.	0.5	0
123	The TBX1 Transcription Factor in Cardiac Remodeling After Myocardial Infarction. Revista Espanola De Cardiologia (English Ed), 2016, 69, 1042-1050.	0.4	0
124	The Importance of Family-genetic Screening: The Phenotype Caused by the p.L3778F Ryanodine Receptor Mutation is Likely Less Severe Than Previously Thought. Revista Espanola De Cardiologia (English Ed), 2016, 69, 702-704.	0.4	0
125	Comentarios a los nuevos criterios internacionales para laÂinterpretaciÃ³n del electrocardiograma delÂdeportista. Revista Espanola De Cardiologia, 2017, 70, 983-990.	0.6	0
126	IKs Computational Modeling to Enforce the Investigation of D242N, a KV7.1 LQTS Mutation. , 2017, , .		0

#	Article	IF	Citations
127	D242N, a KV7.1 LQTS Mutation Uncovers a KEY Residue for IKS Voltage Dependence. Biophysical Journal, 2018, 114, 307a.	0.2	0
128	Reply. Journal of the American College of Cardiology, 2019, 73, 1366-1367.	1.2	0
129	Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. Journal of Clinical Investigation, 2003, 111, 925-925.	3.9	0
130	Hypertrophic Obstructive Cardiomyopathy and Takotsubo Syndrome: Could They Coexist?. Archives of Cardiovascular Imaging, 2015, 3, .	0.2	0
131	Factores modificadores del fenotipo en la miocardiopatÃa hipertrÃ³fica. Respuesta. Revista Espanola De Cardiologia, 2018, 71, 770-771.	0.6	0
132	Reversal of acute pulmonary oedema with beta-blockers in hypertrophic cardiomyopathy. European Journal of Echocardiography, 2003, 4, 71-2.	2.3	0